In Brief This Week is a column containing news items that our readers may have missed during the week.
The firm, which now majority-owned by Life Technologies, also posted a sharp gain in its earnings before interest and taxes.
Life Tech now owns 74 percent of the synthetic gene company.
Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.
The agreement gives Applied Biosystems Deutschland approximately 58 percent of GeneArt's shares.
A proposed HHS guidance for synthetic biology roughly fits a harmonization effort started by the International Gene Synthesis Consortium.
Five firms have formed the International Gene Synthesis Consortium to set gene and customer screening protocols that address security concerns.
The firm's sales increased despite the expiration of an NIH contract.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.